MOREINX is a Swedish Research and Development company specializing in the development and commercialization of CANQURA, its patented nano-based G3 Technology in the areas of Oncology and ADJUVAQ Vaccine Adjuvant. We currently have several ongoing collaborations and alliances globally. Our goal is to advance scientific research and to deliver innovative, differentiated solutions that provide value to patients, physicians and health care systems around the world.
Trials for AML start new phase at Karolinksa. Read the Press Release
Deal signed with Brenntag Biosector A/S, world leading adjuvant producer . Read the Press Release